作者: M. Laburthe , A. Couvineau , P. Nicole
DOI: 10.1007/978-1-4615-0243-2_4
关键词:
摘要: PACAP (Arimura and Shioda, 1995; Vaudry et al, 2000) VIP (Said, 1986; Laburthe 1999) are two prominent neuropeptides which have wide distribution in peripheral central nervous systems large spectrum of biological actions. The 28-aminoacid peptide was discovered 1970 (Said Mutt, 1970) receptors were shortly described the seventies (Laburthe 1993; for review). isolated much later 1989 (Miyata 1989) as a 38-aminoacid but shorter form PACAP27 1990) is also present various tissues 2000). sequence shows 68% identity with that humans. Therefore, most closely related peptides terms structure function so-called VIP-secretin family structurally comprises secretin, glucagon glucagon-like I II, histidine isoleucineamide (PHI), helodermin, growth hormone-releasing factor (GRF) gastric inhibitory polypeptide (GIP) 1993). Soon after discovery PACAP, it shown able to bind high affinity classical (Shivers 1991) had specific receptor has very low (Buscail 1990; Gottschall 1990). rapid development cloning nineties provided evidence three subtypes PACAP: VPAC1, VPAC2 PAC1 (see below). In this context, chapter reviews data regarding molecular pharmacology structure-function relationship including special emphasis on from humans rats.